Skip to main content
. Author manuscript; available in PMC: 2021 Oct 22.
Published in final edited form as: J Med Chem. 2020 Oct 15;63(20):11522–11547. doi: 10.1021/acs.jmedchem.0c00531

Figure 4.

Figure 4.

Counter-screening of top 12 FGF14:Nav1.6 inhibitors using luciferase and toxicity assays. (A) After transfecting HEK293 cells with the full-length photinus pyralis luciferase enzyme, cells were incubated with DMSO (0.5%; n = 32 replicates per plate) or a compound 2 analog (25 μM; n = 4 replicates per plate) for one hour, after which the LCA was performed as previously described. F (12, 83) = 0.4481; p > 0.05. (B) To assess the cellular toxicity of compound 2 analogs, the CellTiter Blue reagent was added to each well following luminescence readings in (A). Detection of fluorescence was performed after 18 h of incubation with the reagent for detecting cellular toxicity. F (12, 83) = 1.817; p > 0.05. Data are mean ± SEM. A one-way ANOVA with post hoc Dunnett’s multiple comparisons test was employed to determine statistical significance.